Enabling Discovery-Scale Access to Antisense and Oligonucleotide Therapeutics
02 Dec 2025
Drug Discovery
- Improving the efficiency of oligonucleotide synthesis and purification to ensure consistent access to high-quality materials for early discovery programs.
- Approaches to evaluate drug metabolism and pharmacokinetics (DMPK) of ASOs.
- Expanding the supply and diversity of modified nucleotides and conjugation reagents to support innovation across antisense and RNA-targeted modalities.
- Strengthening collaboration between discovery groups and CDMOs to bridge gaps in scalability, analytical readiness, and preclinical material availability.
Industry Expert
